Dr. Zlotnick awarded a four year $1.97M NIH grant to study and regulate assembly of HBV capsids.
The Ziarek lab published a new article in Cell Reports, entitled “Ligands selectively tune the local and global motions of neurotensin receptor 1 (NTS1)”.
Edward Sarrain, a fourth year PhD candidate at Hengyao Niu’s lab, has been awarded an NIH National Cancer Institute F31 fellowship.
An IU team led by the Bochman lab was awarded an S10 High-End Instrumentation grant from the National Institutes of Health for the purchase of a Q-Trap from LUMICKS.
Nora Gibes, fourth year student, wins a "Best Oral Presentation" award.
Tucker Shriver, a second year student in the Ziarek lab, is awarded a two-year NIDA Integrated Training in Drug Abuse Research Fellowship.
The lab of Joshua Ziarek has published a new article in Protein Science, entitled “A method for selective 19F-labeling absent of protein sequestration (SLAPS).”
Patrick Laughlin is awarded a Quantitative Chemical Biology Graduate Fellowship.
A team of IU and IUSM researchers led by Matt Bochman was recently awarded an S10 High-End Instrumentation Grant from the National Institutes of Health to purchase a C-Trap from LUMICKS.
Student Tariq Hussain won an award for his poster at the FASEB Virus Structure and Assembly Conference.
The lab of Stephen Bell has published a new article in Nature Microbiology, entitled "Chromosome organization affects genome evolution in Sulfolobus archaea."
Details for the Biochemistry Retreat at the Monroe Convention Center.
“The investigations of Stephen Bell have strengthened our understanding of the origins of life. Chair of the Department of Molecular and Cellular Biochemistry and professor of biology in the College of Arts and Sciences, Stephen is a global leader in chromosome biology through his study of organisms living in extreme conditions.”
Door Pharmaceuticals, a company founded by MCB faculty member Adam Zlotnick, presented a paper at the International HBV Meeting
Door Pharmaceuticals, a company founded by MCB faculty member Adam Zlotnick, presented a paper at the International HBV Meeting (September 21, 2021). Members of the Door team showed that a small molecule that binds the HBV core protein could suppress HBV production. The Door team speculates that the molecule acts by inhibiting transcription of viral RNA.